Wockhardt Limited has informed the Exchange about Investor Presentation
Ref. No.: WOCK/SEC/SE/2021-22/136
8th March, 2022
BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001
National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051
Scrip Code: 532300
NSE Symbol: WOCKPHARMA
Dear Sir/Madam,
Sub: Investor Presentation.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith for your information a copy of the latest investor presentation of the Company.
You are requested to kindly take the same on record.
Thanking you,
for Wockhardt Limited
Debashis Dey Company Secretary
Project Liberty Opportunity to invest in US pharma business
Investors Presentation 2022
Safe harbor
The Wockhardt Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, a
rights issue of its equity shares and has filed a Letter of Offer. The Letter of Offer is available on the website of the SEBI at
https://www.sebi.gov.in, the website of BSE at https://www.bseindia.com, the website of NSE at https://www.nseindia.com,
the website of the Lead Manager at www.ambit.co and the website of the registrar to the Issue at www.linkintime.co.in.
Investors should note that investment in equity shares involves a high degree of risk. For details, potential investors should
refer to the Letter of Offer, including the section titled “Risk Factors”.”
Strictly confidential | Page 2
Snapshot of Wockhardt
Net Sales Revenues (9M FY22)
EBITDA (9M FY22)
Profit after tax (9M FY22)
INR 2,575 Cr
12 manufacturing facilities across world
INR 331 Cr
3 R&D centres one each in India, UK, USA
INR 32 Cr
Over 520 scientists with over 80 PhD’s; Drug Discovery team > 150 associates
Net Debt-Equity Ratio
0.34x1
~ 5,400 employees3 globally with over 20% employees4 based outside India
International business
>80%2
3,214 patents filed; 793 patents granted
Pharmaceuticals & API
Vaccines
Diabetes Biosimilars
Novel Antibiotics
1 - 9M FY 21-22. Excluding promoter debt & preference capital & net of Cash & cash equivalents and other Bank balances 2 - For the year FY 2020-21 3- Includes approximately 1,500 contract employees 4- For the 3,900 employees on payroll of Company
Strictly confidential | Page 3
Financial highlights
Net Sales Revenues in INR Cr.
EBITDA in INR Cr.
24% YOY growth
2,844
2,708
2,575
245
331
FY 19-20
FY 20-21
9M FY 21-22
FY 19-20
-47 FY 20-21
9M FY 21-22
PAT (Continued operations) after exceptional items in INR Cr.
Reduction in long term debts* in INR Cr.
-138
-296
32
FY 19-20
FY 20-21
9M FY 21-22
2,045
1,259
1,084
Mar-20
Mar-21
Dec-21
*Excluding promoter debt & preference capital
Strictly confidential | Page 4
Net Debt : Equity @ 0.34*
Total Equity increased by >INR 700 Cr. ; Total Borrowings Reduction by > INR 1,000 Cr.
Total Equity INR Cr.
Total Borrowings INR Cr.*
3,057
3,760
3,774
2,632
1,853
1,569
FY 19-20
FY 20-21
9M FY 21-22
FY 19-20
FY 20-21
9M FY 21-22
Cash & cash equivalents and other Bank balances INR Cr.
Net Debt-Equity Ratio *
268
292
285
0.77
0.42
0.34
FY 19-20
FY 20-21
9M FY 21-22
FY 19-20
FY 20-21
9M FY 21-22
*9M FY 21-22. Excluding promoter debt & preference capital & net of Cash & cash equivalents and other Bank balances
Strictly confidential | Page 5
Future Growth drivers
2 years growth drivers
1
2
3
Vaccines - Focus on COVID-19 Vaccines
Diabetes Biosimilars for Emerging markets
Re-organized business structure & leadership
5 years growth drivers
Novel drug discovery
Diabetes Biosimilars in US & Europe
1
2
Strictly confidential | Page 6
Growth drivers for next 2 years
1
Vaccines - Focus on COVID-19 Vaccines
Global CMO
Supply to UK Govt.
>100 Mn Doses supplied
Flexibility of supplies from
Fill-finish supply of Astra
existing India & UK sites
Zeneca / University of Oxford
COVID-19 Vaccine to UK Govt.
Strictly confidential | Page 7
Growth drivers for next 2 years
2
Diabetes Biosimilars for Emerging markets
Focus on Recombinant Human Insulin and Insulin Glargine in emerging markets
Manufacturing infrastructure ready
API + Formulation
Low cost manufacturing
Registered in emerging markets
> 25 markets
Under registration in 12 countries
Integrated end to end capabilities
Development to marketing
Own patented device
Strictly confidential | Page 8
Growth drivers for next 2 years:
3
Re-organized business structure & leadership
A
Renew leadership
B
Focus markets
UK
India
Emerging markets
USA
C
Wockhardt selected by Indian Government’s Production Linked Incentive (PLI) Scheme
Strictly confidential | Page 9
Growth drivers for next 5 years
1
Novel drug discovery – focus on Antibiotics against resistant infections
6
QIDP* grant from US FDA for Wockhardt’s 6 novel antibiotics
WCK 5222 (Cephalosporin + β-lactam enhancer) - Destination therapy for XDR Gram Negative Acinetobacter & Pseudomonas
Pre-clinical
Phase I
Phase II1
Global Phase III
C o m p l e t e d
Initiated
Followed by Regulatory filing
Planned completion by end of CY20232
*- Qualified Infectious Disease Product (QIDP) status granted by US FDA eligible for fast track development process and
priority review. QIDP status also grants five year extension to the market exclusivity in the United States
1.Phase II: Waiver 2.Based on management estimates
Strictly confidential | Page 10
WCK 5222 differentiation
Activity against resistant infection
Pipeline Drugs
Approved Drugs
Organism/ Resistance Mech.
WCK 52221
Product 1
Product 2
Product 3
Product 4
Product 5
Product 6
Product 7
Product 8
Product 9
K. pneumoniae (ESβL)
K. pneumoniae (KPC)
K. pneumoniae (MβL)
E. coli (PBP3 insert+ESBL/Class C)
E. coli (MβL± PBP3 Insert)
Enterobacter (AmpC)
Proteus (ESβL, Class C)
P. aeruginosa (AmpC + oprD +Efflux)
P. aeruginosa (Oxa, oprD + Efflux)
P. aeruginosa (MβL)
A. baumannii (CHDL, OXA)
S. maltophilia MDR/XDR
1.WCK 5222: Cifepime + Zidebactam`
MIC
MIC
In vivo
In vivo
Most Isolates Susceptible
Variable Susceptibility
Most Isolates Resistant
MIC
In vivo
Most Isolates Resistant
Sub-optimal Perfomance for Strains with MIC ≤ Breakpoint
Strictly confidential | Page 11
Novel drug discovery pipeline – focus on Antibiotics against resistant infections
Robust product pipeline
Development Stage
Target market
1
2
3
4
Emrok IV / Emrok O
Launched in India
Emerging Markets
WCK 4873
Phase III
Emerging Markets
WCK 4282
Phase III
Global
WCK 6777
Phase I
US
Partnered with Jemincare for Greater China
Strictly confidential | Page 12
Growth drivers for next 5 years
2
Diabetes Biosimilars for US & Europe
Biosimilars Portfolio of Insulin & GLP-1 analogs
Product
Type
Development Stage
Insulin Glargine
Long acting analogue
GMP batches for Clinical
Insulin Aspart
Rapid acting analogue
Product developed / Under testing
Insulin Lispro
Rapid acting analogue
Product developed / Under testing
Liraglutide
GLP-1 analogue
Under development
1
2
3
4
Limited competition
Manufacturing capacity ready
Integrated end to end capabilities from development to marketing
Strictly confidential | Page 13
Leadership Team
Dr. Habil Khorakhiwala Founder and Executive Chairman
Ravi Limaye
Ajay Sahni
Dr. Mahesh Patel
Managing Director- Wockhardt UK
Managing Director -Wockhardt Bio AG / France / Pinewood
Chief Scientific Officer
Prakash Gupta
Lalit Aggarwal
Pradnya Deshmukh
Dr. Vijayesh Gupta
President-Global Supply Chain
President - Manufacturing
President – Quality & Compliance
President – Global Strategy, Growth Initiatives
Renewed Leadership (Joined in last 1 year)
Dr. Murtaza Khorakhiwala Managing Director
President - North America
President - Emerging Markets
Head-India Branded Business
Chief Digital Officer
Robert Spina
Vivek Bachhawat
Amrut Medhekar
Avijit Deb
Strictly confidential | Page 14
Board of Directors
Mr. Aman Mehta
Independent Director
Mr. D. S. Brar
Independent Director
Dr. Sanjaya Baru
Independent Director
Dr. Habil Khorakiwala Founder and Executive Chairman
► Ex-President, FICCI ► Ex-President, IPA ► Ex-Chancellor, JHU, New Delhi
► Past Head of HSBC operations in India ► Over 35 years of experience
► Ex-CEO & MD, Ranbaxy Laboratories ► Founder of GVK Biosciences Pvt. Ltd ► Ex-Director, RBI ► Member on Board, NIPER; ► Ex-Chairman,Indian MNC Council of CII
► Ex-Official spokesman PMO ► Ex-Secretary General, FICCI ► Ex-Director, IISS London ► Ex-Chief Editor, The Financial Express
Mrs. Tasneem Mehta Independent Director
Mr. Vinesh Kumar Jairath Independent Director
Mr. Akhilesh Gupta Independent Director
► Dr. Bhau Daji Lad Museum, Managing
Trustee and Honorary Director ► Former Vice Chairman & Mumbai
► Ex-IAS, GoM and GoI ► Ex- Managing Director, SICOM ► Ex Principal Secretary of Industries GoM
► Ex-Chairman, Blackstone India ► Ex-CEO, Corporate Development,
Reliance Industries Limited
Convenor, INTACH
► Advisory Council of Graduate School of Business , Stanford University
Dr. Murtaza Khorakiwala Managing Director
► Immediate past President, International Chamber of Commerce (ICC), India
► Ex-President, BMA ► Member, Executive Committee, IPA
Mrs. Rima Marphatia Nominee Director
Dr. Huzaifa Khorakiwala Executive Director
Ms. Zahabiya Khorakiwala
Non-Executive Director
► Chief General Manager, Exim bank ► Ex-Member of RBI committee on
financial Institutions
► Trustee & CEO, Wockhardt Foundation ► Founder, The World Peacekeepers ► 13 Honorary Doctorates & a Knighthood
► Managing Director, Wockhardt
Hospitals
► BOD, RPG Life Sciences Ltd
Strictly confidential | Page 15
Abbreviations
• API: Active Pharmaceutical Ingredient
• CMO: Contract Manufacturing Organization
• EBITDA: Earnings before Interest, Tax, Depreciation and Amortization
• GLP-1: Glucagon like Peptide-1
• GMP: Good Manufacturing Practice
• KOL: Key Opinion Leader
• MDR: Multi Drug Resistant
• MIC: Minimum Inhibitory Concentration
• PAT: Profit After Tax
• QIDP: Qualified Infectious Disease Product
• US FDA: United States Food & Drug Administration
• XDR: Extremely Drug Resistant
Strictly confidential | Page 16
Life wins !
Impacting Life
Saving Life
Affordability
Stakeholders
Strictly confidential | Page 17